Hemoglobin (Hb) adducts, formed by the neurotoxic agent acrylamide (AA) and its genotoxic metabolite glycidamide (GA), were measured in the rat by means ofa method for simultaneous determination ofthe adducts formed to cysteine. A novel, nonlinear dosimetric model was developed to describe Hb showing an impact ofphenobarbital induction on the neurotoxicity of AA in rats, indicated to us that AA underwent further metabolism in a cytochrome P-450-mediated reaction. In an attempt to confirm the hypothesis that AA was metabolically oxidized to the epoxide GA, we analyzed Hb hydrolysates from rats treated with AA and were able to identify S-(2-carboxy-2-hydroxyethyl)-cysteine, the adduct formed by GA, by means of GC-MS (4) (Fig. 1) .
The development of analytical methods for quantitating adducts formed by electrophilic substances with macromolecules such as hemoglobin (Hb) and DNA has made significant progress over the past decades, and such adducts have been proposed as biomarkers for use in epidemiological studies aiming to monitor human exposure to toxic agents. In contrast, mathematical models for adduct formation, crucial for the use ofthese biomarkers for human risk estimation, have been relatively unsophisticated and essentially limited to the linear model. Our work with Hb adduct formation by the neurotoxic agent acrylamide (AA) and its genotoxic metabolite glycidamide (GA) prompted us to develop a nonlinear mathematical model for adduct formation applicable also at the high exposures where capacity-limited processes come into play and toxic effects are commonly observed in experimental organisms.
Humans are exposed to AA mainly in the chemical industry, molecular biology laboratories, and grouting operations (1 showing an impact ofphenobarbital induction on the neurotoxicity of AA in rats, indicated to us that AA underwent further metabolism in a cytochrome P-450-mediated reaction. In an attempt to confirm the hypothesis that AA was metabolically oxidized to the epoxide GA, we analyzed Hb hydrolysates from rats treated with AA and were able to identify S-(2-carboxy-2-hydroxyethyl)-cysteine, the adduct formed by GA, by means of GC-MS (4) (Fig. 1 ). In contrast, adduct formation by either AA or its metabolite GA in rats treated with an initial concentration, [AA] o, of AA in the range 0-100 mg/kg body weight was inconsistent with a linear model. Thus, while adduct formation by AA was convex (3), approaching linearity at high concentrations, adduct formation by°G A was a concave function of the injected concentration, presumably reflecting a saturable Michaelis-Menten type of kinetics for the metabolic conversion of AA to GA. The following kinetic scenarios for AA and GA, respectively, were thus assumed: To evaluate the role of GA in the induction of toxic effects associated with AA exposure, a series of experiments was undertaken to study its toxicological properties and quantitative relevance as a metabolite. It was thus found that AA itself was primarily responsible for causing peripheral neuropathy as judged from the inability of GA to cause neuropathological damage to sciatic nerves or have an effect in the hindlimb splay test in treated animals (5, Deng et al., in preparation). On the other hand, GA had a strong impact on body weight, sperm cell viability, and epididymal daily sperm production in male rats (5), implicating a role of GA in the induction of male reproductive toxicity in rodents given AA. Already prior to its discovery as a metabolite ofAA, GA had been shown to give a positive response in the Ames test (6) . It was thus hypothesized (4) that GA was the agent responsible for the cancer-initiating properties associated with AA exposure in experimental animals.
To be able to measure tissue doses (7), DAA and DGA, of both AA and GA, for risk assessment of neurotoxic (DAA) or reproductive and genotoxic effects (DGA), respectively, we developed a GC-MS technique that allows us to simultaneously determine Hb adducts to cysteine formed by both electrophiles (8) (Fig. 1) This work was financially supported by Cooperative Agreement CR-816768 with the U.S. EPA. Although the research described in this article has been supported by the U.S. Environmental Protection Agency, it has not been subjected to Agency review and therefore does not necessarily reflect the views of the Agency, and no official endorsement should be inferred.
